The FDA approved a new stent made by Boston Scientific (BSX) seven months earlier than expected, sending shares of the device-maker 5.5% higher at the opening bell. They are now trading about 2.5% higher. Investors had been concerned about a rare problem that caused some stents to become deformed after it was implanted, Reuters notes, but the approval reduces those worries. The FDA had said the stents were safe when used for authorized uses.
The Promus Element Plus drug-eluting heart stent that was approved was already available overseas.
No comments:
Post a Comment